...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Plugging along but.....

Nothing new to indicate anywhere close to a prospective liquidity event....still could take years....also this presentation definitely lacks a "retorical flourish" that a shareholder would like to hear.

Meanwhile back to the encouragement of RVX...will wait with bated breath!

Share
New Message
Please login to post a reply